There has only been limited research into the predictors of readmission in bipolar disorder. We carried out a 1-year follow-up of patients discharged from a single mental health unit following admission for treatment of an acute bipolar episode. Of 519 patients followed up for 1 year, 167 (32.2%) were readmitted. There was no association between readmission and any drug regimen. Prescription of antidepressants at discharge was not associated with increased risk of readmission [odds ratio (OR): 0.99, 95% confidence interval (CI): 0.98-1.01]. Among demographic factors, only smoking (OR: 1.75, 95% CI: 1.14-2.75) and age range of 42-53 years (OR: 1.99, 95% CI: 1.15-3.43) conferred an increased risk of readmission. Individually optimized drug treatment regimens are equally effective in practice. It is not clear why smoking is associated with readmission. Int Clin Psychopharmacol 32:115-120
Introduction
Bipolar disorder (BD) is a complex and life-long condition that requires wide-ranging clinical interventions, the mainstay of which are prescribed medications. In determining which drugs to prescribe, clinicians often look to guidelines based on comprehensive meta-analyses of controlled trials. These studies indicate the most effective single treatments in mania (Cipriani et al., 2011) , bipolar depression (Taylor et al., 2014) and in the prophylaxis of relapse in BD (Ghaemi et al., 2008; Vieta et al., 2011) . Rather less is known about outcomes from the use of combinations (Smith et al., 2007) and older drugs, whether alone or in combination (Tohen et al., 2001) .
Formal clinical trials report on efficacy (what can work in trials) rather than effectiveness (what does work in practice)
. The latter is evaluated in naturalistic, noninterventional studies of normal clinical practice. In BD, as in other conditions, these studies take two forms: database studies that include large numbers of patients, but have limited information on clinical or demographic details, and observational studies, which more closely follow a smaller number of patients, often from a single healthcare unit.
There are numerous studies of both kinds in BD (Fekadu et al., 2006; Kim et al., 2009; Hayes et al., 2016; Peselow et al., 2016) , but few of these address the real-life complexity of BD treatment (patients on multiple drug regimens are often excluded) or outcomes in patients discharged from hospital following an acute episode (most are studies of outpatients).
Here, we report on our nonexclusive study of patients discharged from our hospital on a wide range of drug regimens in which we aimed to uncover moderators of outcome following discharge. The aim of the study was to determine factors associated with an increased risk of readmission following discharge from hospital after treatment for an acute bipolar episode.
Materials and methods
All in-patient admissions that occurred between 1 January 2010 and 31 December 2011 and were formally allocated an F30 (manic episode) or an F31 (bipolar affective disorder) ICD-10 diagnosis (at admission or discharge) were identified from our NHS Trust's anonymized Clinical Record Interactive Search (CRIS) system. Detailed patient information was extracted from the Trust's electronic Patient Journey System (ePJS).
We tracked outcomes in all patients identified from discharge until readmission or, if not readmitted, for up to 1 year. Our primary outcome was readmission to hospital.
Drug regimens
We recorded all drugs prescribed at discharge without an a priori view on how these regimens would be later classified. We were particularly interested in the effects of antidepressant prescription on readmission and determined to analyse outcome with those prescribed any antidepressant versus no antidepressant, should there be sufficient patients prescribed antidepressants. Other regimens were also classified post-hoc having viewed the range of regimens recorded.
Demographic details
We recorded all patient-level data reliably available to use from the ePJS system (sex, age, ethnicity, diagnosis) and other data deemed a priori as factors of interest (smoking, BMI, illicit drug or alcohol use).
Statistical analysis
Descriptive statistics were calculated for all patients. Readmission was defined as being readmitted within 1 year of discharge. Unadjusted differences in characteristics between readmission status were compared using an independent t-test for continuous data and the χ 2 -test for categorical data. The time to readmission curve was plotted using the Kaplan-Meier method. Associations between patient characteristics and readmission status were then explored using logistic regression. The number of readmissions to variable ratio was lower than the recognized minimum of 10 (Harrell, 2001) . To avoid overfitting and increasing the Standard Errors of coefficients, the least absolute shrinkage and selection operator method to shrink regression coefficients towards the null value was used (Tibshirani, 2011) . The approach is recommended over using a stepwise approach to variable selection or univariate screening techniques (Pavlou et al., 2015) . Dummy variables were constructed for nominal variables. The association of 'medication on discharge' with 'readmission within 1 year' was examined using two approaches. The first model included medication categorized by drug class and use of depot and the second model included individual drugs of interest and the generation (first or second) of antipsychotic. The assumption of linearity on the logit scale was examined by plotting the logit of the proportion on readmission across categorized groups for age. As the linearity assumption was not deemed reasonable, the variable was categorized on the basis of quartiles and treated as a dummy variable with the lowest category as a reference. Model specification was examined using the link test and the observed versus predicted values (calibration) were examined using Hosmer and Lemeshow's goodness-of-fit test. All analyses were carried out in (Stata, version 13; StataCorp LLC, Texas, USA).
Results
A total of 716 patients were identified through CRIS; 519 patients fulfilled the inclusion criteria of F30 or F31 diagnosis. Patients were excluded if an F30 or an F31 diagnosis was not fulfilled (n = 98), as were patients who died before discharge (n = 6); patients without complete records for data extraction (n = 3); patients who were discharged from Trust services (lost to follow-up) (n = 10); and those patients who were admitted in 2010 and readmitted in 2011 (i.e. duplicates) (n = 80).
Overall, 167 of 519 (32·2%) patients were readmitted during the year's follow-up (Fig. 1) . Smoking was statistically associated with increased likelihood of readmission Cumulative proportion of readmissions by time. On first admission.
-69.5% of those readmitted were smokers, but only 56.8% of those not readmitted (P = 0.006). Those readmitted also had a higher mean BMI (29.5) than those not readmitted (26.0) (P < 0.001), but these data were available only for 206 patients. Table 1 describes the cohort's individual patient characteristics.
No individual medication or multiple medication regimen was statistically associated with rehospitalization (Table 2 ) and, numerically, the outcomes were very similar. Overall, 69 (13.8%) patients were discharged on an antidepressant, but this did not affect risk of readmission (P = 0.962). Among these patients, a minority were prescribed antidepressants alone (n = 4; all selective serotonin reuptake inhibitors), but most (n = 65; 34 selective serotonin reuptake inhibitors, 14 serotoninnorepinephrine reuptake inhibitors, 10 mirtazapine, five amitriptyline and two reboxetine) were prescribed an antidepressant along with a mood stabilizer or antipsychotic.
In the logistic regression model ( 
Discussion
In our cohort of consecutive patients discharged from hospital with a diagnosis of mania or BD, smoking status, higher BMI and an age range of 42-53 years were associated with an increased risk of readmission. No individual drug or drug regimen, including the prescription of antidepressants, was associated with altered risk of readmission. Overall, just less than a third of patients were rehospitalized in the year-long follow-up.
The rehospitalization rate in this study is 32.2%, which is somewhat higher than that observed in other studies. In an analysis of the US-based naturalistic STEP-BD study, 28.8% of 858 participants relapsed within 1 year of recovery . In an analysis of naturalistic and controlled studies (Vazquez et al., 2015) , the yearly recurrence rates were 26.3 and 21.9%, respectively. However, bipolar relapse or recurrence does not always result in rehospitalization: in one analysis (Hong et al., 2010), only 60% of relapsers were admitted (although not all had been admitted for the index episode).
Comparative data for rehospitalization suggest, for example, that around 10% of treated patients are readmitted within 90 days (Kim et al., 2009 ) and 17-25% over 1 year (Patel et al., 2005; Woo et al., 2014) . The last two figures are most relevant to our findings as both measured time from hospital discharge to readmission (although the first included only first-episode patients).
The reasons for our relatively high readmission rate are difficult to determine precisely, although our particular environment -patients treated in a publicly funded health system in a socially deprived urban context -is certainly relevant as is the high prevalence of substance misuse, especially skunk-like cannabis (Di Forti et al., 2015) . Treatment in a specialized mood disorder clinic early in the course of BD has been shown to markedly reduce readmission to psychiatric hospital and increase satisfaction with care (Kessing et al., 2013) , although, somewhat surprisingly, this approach has not yet been widely adopted.
Smoking in BD has previously been linked to a greater severity of symptoms, poorer functioning and a history of suicide attempts (Waxmonsky et al., 2005; Ostacher et al., 2006 Ostacher et al., , 2009 . The reasons for this association are not clear, but smoking status may be linked to impulsivity (Ostacher et al., , 2009 , a higher prevalence of attention deficit hyperactivity disorder symptoms (Waxmonsky et al., 2005) and induction of drugmetabolizing enzymes (Kroon, 2007) . In fact, smoking status may simply be a marker for poor prognostic indicators in biopolar affective disorder: rapid cycling, substance misuse and co-morbid psychiatric conditions are each associated with smoking (Waxmonsky et al., 2005) .
Higher body weight has also previously been linked to worsened outcomes in BD (Kim et al., 2008; Maina et al., 2008; Calkin et al., 2009) . Again, the reasons for this remain uncertain, but certainly higher body weight would mean that higher doses of drugs would be needed. Also, increased BMI may reflect relatively greater disturbance in the hypothalamic-pituitary-adrenal axis, which in turn may be associated with a greater disease severity (Maina et al., 2008) . The age range found in our study (42-53 years) likely reflects a peak age of risk for readmission because of the progressive nature of BD for many patients (Angst and Sellaro, 2000) coupled with increased death rate causing attrition from this age (Grande et al., 2016) .
We did not find any associations between drug therapy and rehospitalization, although we had hypothesized that those discharged on antidepressants would be seen to have a worse outcome (particularly relapse into mania, leading to readmission) as suggested by randomizedcontrolled trials (Ghaemi et al., 2008) . The absence of any associations with readmission for any drug or drug regimen was also surprising, given the results of previous studies (Kim et al., 2011; Hayes et al., 2016; Peselow et al., 2016) . There are at least three possible explanations for our findings. First, it may have been that we had insufficient patients (and therefore statistical power) to show differences in a (low power) binary outcome such as readmission. Against this is the observation that none of our findings approached significance and all were remarkably numerically similar: no particular trends were observed (with two exceptions of poor outcome with aripiprazole and depot antipsychotics). Second, it is possible that by including those patients on complex medication regimens, we 'evened out' differences between the therapeutic effects of individual drugs. Third (and perhaps most likely), it may be that clinically optimized complex regimens (which can be fine-tuned following discharge) yield broadly similar outcomes in practice, as opposed to the unoptimized, randomly assigned, rigid treatments of controlled trials. For example, the coprescription of a mood-stabilizing drug might mitigate the manic switching propensity of antidepressants -65 of 69 patients in our study prescribed antidepressants also received a classical mood stabilizer or mood-stabilizing antipsychotic. However, this cannot be established with any certainty as we did not record the reason for admission following discharge (although nearly all of our admissions are for mania or hypomania). Uncertainties remain about the benefits and harms of antidepressant use in BD (Pacchiarotti et al., 2013) , but our data suggest that these should be further investigated in naturalistic studies. Our data also weakly suggest a negative effect for depot antipsychotics (39.4% of those on depot were readmitted). However, this was not a statistically significant association and may reflect selection bias: the naturalistic use of depots in patients known to be poor compliers. Similarly, the relatively poor outcome with aripiprazole (42.1% readmitted) did not approach statistical significance in any analysis.
Drug regimens prescribed to patients discharged from hospital after admission for acute mania do not appear to affect the risk of rehospitalization. The adverse effect of smoking on rehospitalization is striking and requires further investigation to determine to what extent smoking directly influences readmission.
